Wellington Management Group
CRVS icon

Wellington Management Group’s Corvus Pharmaceuticals CRVS Stock Holding History

Wellington Management Group’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.9M Buy
2,318,517
+2,003,834
+637% +$32M 0.01% 848
2025
Q4 		$2.42M Buy
314,683
+134,508
+75% +$1.06M ﹤0.01% 1553
2025
Q3 		$1.33M Buy
180,175
+77,828
+76% +$398K ﹤0.01% 1719
2025
Q2 		$409K Sell
102,347
-2,525
-2% -$9.19K ﹤0.01% 1847
2025
Q1 		$333K Buy
+104,872
New +$494K ﹤0.01% 1865

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Wellington Management Group's CRVS Position: Q1 2026 in Review

Wellington Management Group increased its Corvus Pharmaceuticals (CRVS) stake by 637% in Q1 2026, buying an estimated $32M and bringing the position to 2,318,517 shares worth $33.9M. The position accounts for 0.01% of the portfolio, ranked #848.

Wellington Management Group first reported a position in CRVS in Q1 2025 and has held it in 5 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Wellington Management Group held 2,318,517 shares of Corvus Pharmaceuticals worth $33.9M as of Q1 2026.
  • Wellington Management Group bought 2,003,834 Corvus Pharmaceuticals shares in Q1 2026, an estimated $32M.
  • Corvus Pharmaceuticals made up 0.01% of Wellington Management Group's portfolio in Q1 2026, its #848 holding.
  • Wellington Management Group first reported a position in Corvus Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Wellington Management Group's 13F filing for Q1 2026, filed 15 May 2026.